These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 36709596)

  • 1. Immune checkpoint receptors in autoimmunity.
    Burke KP; Patterson DG; Liang D; Sharpe AH
    Curr Opin Immunol; 2023 Feb; 80():102283. PubMed ID: 36709596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy.
    Guram K; Kim SS; Wu V; Sanders PD; Patel S; Schoenberger SP; Cohen EEW; Chen SY; Sharabi AB
    Front Immunol; 2019; 10():491. PubMed ID: 30936880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.
    Shi X; Li CW; Tan LC; Wen SS; Liao T; Zhang Y; Chen TZ; Ma B; Yu PC; Lu ZW; Qu N; Wang Y; Shi RL; Wang YL; Ji QH; Wei WJ
    J Clin Endocrinol Metab; 2021 Jan; 106(1):120-132. PubMed ID: 33000173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
    Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
    Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TIGIT: An emerging immune checkpoint target for immunotherapy in autoimmune disease and cancer.
    Zhao J; Li L; Yin H; Feng X; Lu Q
    Int Immunopharmacol; 2023 Jul; 120():110358. PubMed ID: 37262959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitors associated cardiovascular immune-related adverse events.
    Jo W; Won T; Daoud A; Čiháková D
    Front Immunol; 2024; 15():1340373. PubMed ID: 38375475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint biology in health & disease: Immune checkpoint biology and autoimmunity in cancer patients.
    Van Mol P; Donders E; Lambrechts D; Wauters E
    Int Rev Cell Mol Biol; 2024; 382():181-206. PubMed ID: 38225103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Not Available].
    Senant M; Giusti D; Weiss L; Dragon-Durey MA
    Bull Cancer; 2016 Nov; 103 Suppl 1():S175-S185. PubMed ID: 28057182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis.
    Solorzano-Ibarra F; Alejandre-Gonzalez AG; Ortiz-Lazareno PC; Bastidas-Ramirez BE; Zepeda-Moreno A; Tellez-Bañuelos MC; Banu N; Carrillo-Garibaldi OJ; Chavira-Alvarado A; Bueno-Topete MR; Del Toro-Arreola S; Haramati J
    Clin Exp Immunol; 2021 Apr; 204(1):78-95. PubMed ID: 33306195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.
    Fife BT; Bluestone JA
    Immunol Rev; 2008 Aug; 224():166-82. PubMed ID: 18759926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1, CTLA-4, LAG-3, and TIGIT: The roles of immune checkpoint receptors on the regulation of human NK cell phenotype and functions.
    Esen F; Deniz G; Aktas EC
    Immunol Lett; 2021 Dec; 240():15-23. PubMed ID: 34599946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune-related adverse events in various organs caused by immune checkpoint inhibitors.
    Okiyama N; Tanaka R
    Allergol Int; 2022 Apr; 71(2):169-178. PubMed ID: 35101349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Anti-human T Cell Immunoreceptor with Ig and ITIM Domains (TIGIT) Monoclonal Antibodies for Flow Cytometry.
    Takei J; Asano T; Nanamiya R; Nakamura T; Yanaka M; Hosono H; Tanaka T; Sano M; Kaneko MK; Harada H; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2021 Apr; 40(2):71-75. PubMed ID: 33900817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T cell checkpoint regulators in the heart.
    Grabie N; Lichtman AH; Padera R
    Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. V-Set and immunoglobulin domain containing (VSIG) proteins as emerging immune checkpoint targets for cancer immunotherapy.
    Zhou X; Khan S; Huang D; Li L
    Front Immunol; 2022; 13():938470. PubMed ID: 36189222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
    Qin S; Xu L; Yi M; Yu S; Wu K; Luo S
    Mol Cancer; 2019 Nov; 18(1):155. PubMed ID: 31690319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules.
    D'Arrigo P; Tufano M; Rea A; Vigorito V; Novizio N; Russo S; Romano MF; Romano S
    Curr Med Chem; 2020; 27(15):2402-2448. PubMed ID: 30398102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Co-inhibitory Receptors CTLA-4, PD-1, TIGIT, LAG-3, and TIM-3 in Upper Tract Urothelial Carcinomas: A Large Cohort Study.
    Jin S; Shang Z; Wang W; Gu C; Wei Y; Zhu Y; Yang C; Zhang T; Zhu Y; Zhu Y; Wu J; Ye D
    J Immunother; 2023 May; 46(4):154-159. PubMed ID: 37017991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoints and cancer development: Therapeutic implications and future directions.
    Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
    Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.